Judith E. Karp
Division of Hematologic Malignancies
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins Hospital
Baltimore
USA
Name/email consistency: high
- Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Karp, J.E., Thomas, B.M., Greer, J.M., Sorge, C., Gore, S.D., Pratz, K.W., Smith, B.D., Flatten, K.S., Peterson, K., Schneider, P., Mackey, K., Freshwater, T., Levis, M.J., McDevitt, M.A., Carraway, H.E., Gladstone, D.E., Showel, M.M., Loechner, S., Parry, D.A., Horowitz, J.A., Isaacs, R., Kaufmann, S.H. Clin. Cancer Res. (2012)
- Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Karp, J.E., Garrett-Mayer, E., Estey, E.H., Rudek, M.A., Smith, B.D., Greer, J.M., Drye, D.M., Mackey, K., Dorcy, K.S., Gore, S.D., Levis, M.J., McDevitt, M.A., Carraway, H.E., Pratz, K.W., Gladstone, D.E., Showel, M.M., Othus, M., Doyle, L.A., Wright, J.J., Pagel, J.M. Haematologica (2012)
- Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Karp, J.E., Vener, T.I., Raponi, M., Ritchie, E.K., Smith, B.D., Gore, S.D., Morris, L.E., Feldman, E.J., Greer, J.M., Malek, S., Carraway, H.E., Ironside, V., Galkin, S., Levis, M.J., McDevitt, M.A., Roboz, G.R., Gocke, C.D., Derecho, C., Palma, J., Wang, Y., Kaufmann, S.H., Wright, J.J., Garret-Mayer, E. Blood (2012)
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Karp, J.E., Smith, B.D., Resar, L.S., Greer, J.M., Blackford, A., Zhao, M., Moton-Nelson, D., Alino, K., Levis, M.J., Gore, S.D., Joseph, B., Carraway, H., McDevitt, M.A., Bagain, L., Mackey, K., Briel, J., Doyle, L.A., Wright, J.J., Rudek, M.A. Blood (2011)
- Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Karp, J.E., Blackford, A., Smith, B.D., Alino, K., Seung, A.H., Bolaños-Meade, J., Greer, J.M., Carraway, H.E., Gore, S.D., Jones, R.J., Levis, M.J., McDevitt, M.A., Doyle, L.A., Wright, J.J. Leuk. Res. (2010)
- Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Karp, J.E., Flatten, K., Feldman, E.J., Greer, J.M., Loegering, D.A., Ricklis, R.M., Morris, L.E., Ritchie, E., Smith, B.D., Ironside, V., Talbott, T., Roboz, G., Le, S.B., Meng, X.W., Schneider, P.A., Dai, N.T., Adjei, A.A., Gore, S.D., Levis, M.J., Wright, J.J., Garrett-Mayer, E., Kaufmann, S.H. Blood (2009)
- Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Karp, J.E., Smith, B.D., Gojo, I., Lancet, J.E., Greer, J., Klein, M., Morris, L., Levis, M.J., Gore, S.D., Wright, J.J., Garrett-Mayer, E. Clin. Cancer Res. (2008)
- A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Karp, J.E., Giles, F.J., Gojo, I., Morris, L., Greer, J., Johnson, B., Thein, M., Sznol, M., Low, J. Leuk. Res. (2008)
- Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Karp, J.E., Smith, B.D., Levis, M.J., Gore, S.D., Greer, J., Hattenburg, C., Briel, J., Jones, R.J., Wright, J.J., Colevas, A.D. Clin. Cancer Res. (2007)
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Karp, J.E., Ricklis, R.M., Balakrishnan, K., Briel, J., Greer, J., Gore, S.D., Smith, B.D., McDevitt, M.A., Carraway, H., Levis, M.J., Gandhi, V. Blood (2007)
- Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Karp, J.E., Lancet, J.E. Cancer Invest. (2007)
- Trying to improve clinical outcome in AML: lessons from negative trials. Karp, J.E., Smith, B.D. Leuk. Res. (2005)
- Farnesyl transferase inhibition in hematologic malignancies. Karp, J.E. J. Natl. Compr. Canc. Netw (2005)
- Targeting the process of farynesylation for therapy of hematologic malignancies. Karp, J.E., Lancet, J.E. Curr. Mol. Med. (2005)
- Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Karp, J.E., Lancet, J.E. Future. Oncology. (london,. England) (2005)
- Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Karp, J.E., Gojo, I., Pili, R., Gocke, C.D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., Chen, H., Zwiebel, J. Clin. Cancer Res. (2004)
- Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Karp, J.E., Ross, D.D., Yang, W., Tidwell, M.L., Wei, Y., Greer, J., Mann, D.L., Nakanishi, T., Wright, J.J., Colevas, A.D. Clin. Cancer Res. (2003)
